Feedback PLC Expansion of European customer base
22 Oktober 2018 - 8:00AM
RNS Non-Regulatory
TIDMFDBK
Feedback PLC
22 October 2018
Feedback plc
Feedback expands its European customer base with new orders for
TexRAD(R) from prestigious European university hospitals
Cambridge, 22 October 2018: Feedback plc (AIM: FDBK, "Feedback"
or the "Company"), the specialist medical imaging technology
company, announces that its operating company, Feedback Medical
Ltd, has received a number of new significant orders for TexRAD(R)
, its patented image texture analysis technology, from prestigious
university hospitals across Europe.
The orders have come from: Universitair Ziekenhuis Gent,
Belgium; Beaujon Hospital, University Hospital Clichy, Service
d'Imagerie médicale, France; ICNAS Producao Unip. Lda (Coimbra),
Portugal; University of Cagliari - Department of Diagnostic Imaging
and Radiology, Italy. This collection of orders represents the
first for TexRAD(R) in Belgium and Portugal.
The initial areas of research range from Crohn's disease,
aneurysms and carotid imaging, to liver cancer on routinely
acquired standard computed tomography (CT) and magnetic resonance
(MR) images. These research projects will run alongside other
projects in the area of oncology, which is the main focus area for
the Company.
The orders have arisen from an increase in business development
activities during the year. These include scientific presentations
and peer group referrals from previous purchasers of TexRAD(R)
.
TexRAD(R) is now used across Europe and the Company is looking
to expand its existing customer bases in the US and Asia. As
outlined in the recent trading update, the Company has initiated
plans for regulatory approval of TexRAD with the US FDA including
510k as medical device and CFR Chapter 21 part 11 compliance for
use in clinical trials of drug candidates for FDA marketing
approval.
Dr Balaji Ganeshan, Global Business Development Director of
Feedback Medical Ltd, said:
"These recent orders of TexRAD(R) are further validation of
Feedback Medical and our technology. We are taking advantage of our
growing reputation to drive new business. These new business wins
have resulted from having referrals from current customers and
penetrating new country markets. TexRAD(R) is now being used in a
diverse range of research fields which demonstrates the significant
potential and applicability of our technology."
- ENDS -
For further information, please contact:
Feedback plc +44 (0)1954 718072
Alastair Riddell, Executive Chairman IR@fbk.com
Lindsay Melvin, CFO
Instinctif Partners +44 (0)20 7457 2020
Rozi Morris/ Deborah Bell/ Phillip Marriage feedbackplc@instinctif.com
Notes to editors
About Feedback plc
Feedback plc (AIM: FDBK) is a specialist medical imaging
technology company providing innovative software and systems,
through its fully-owned trading subsidiary, Feedback Medical
Limited. Its products advance the work of radiologists, clinicians
and medical researchers by improving workflows and giving unique
insights into diseases, particularly cancer. Feedback Medical works
with customers globally from headquarters in the internationally
renowned scientific hub of Cambridge, UK. Its proprietary
technologies are TexRAD(R) , the quantitative texture analysis tool
and Cadran, a picture archiving communication system (PACS). For
more information, see www.fbk.com
About TexRAD(R) quantitative texture analysis
TexRAD(R) is a patent-protected software tool which extracts and
quantifies texture features in radiological images, assisting
research into all tumour types. In the exciting new field of
radiomics, TexRAD(R) uncovers biomarkers in medical images which
are invisible to the naked eye. TexRAD(R) has featured in over 100
academic publications, won numerous awards and is currently used in
over 50 prestigious institutions worldwide. Feedback Medical
recently launched TexRAD(R) Lung, a software tool for the analysis
of lung cancer, which is CE marked for clinical use in the EU.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFMMZGGMFGRZZ
(END) Dow Jones Newswires
October 22, 2018 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024